Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 801–900 of 1,001
Gustafsson, F., Segura, J., & Ruilope, L. M. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833984b8 · Cited by 13
Cultural Competency, Human Genomics, and the Elimination of Health Disparities
Matthews-Juarez, P., & Juárez, P. D. (2011) · Social Work in Public Health · doi:10.1080/19371918.2011.579043 · Cited by 15
“on health disparities among racial and ethnic minorities away from culturally competency toward genetic explanations (Barrett et al., 2002; Candy et al., 2000; Exner, Dries, Domanski, & Cohn, 2001; Moore, Mason, Green, Hsu, & Liggett, 1999; Pratt, 2005; Taylor et al., 2004).”
BackgroundInfluentialYancy, C. W., Ghali, J. K., Braman, V. M., Sabolinski, M. L., Worcel, M., Archambault, W. T., & Franciosa, J. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.086 · Cited by 13
Self-citationCombining Neuroendocrine Inhibitors in Heart Failure: Reflections on Safety and Efficacy
Jneid, H. M., Moukarbel, G. V., Dawson, B., Hajjar, R. J., & Francis, G. S. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.02.029 · Cited by 15
Management of Acute Decompensated Heart Failure
Dec, G. W. (2007) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2007.02.002 · Cited by 16
An Update On Treatments and Outcomes in Peripartum Cardiomyopathy
Sheppard, R., Rajagopalan, N., Safirstein, J. G., & Briller, J. E. (2014) · Future Cardiology · doi:10.2217/fca.14.23 · Cited by 13
Gulf CARE: Heart failure in the Middle East
Hassan, M. S. (2015) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2015.34 · Cited by 14
Hussey, A., & Weintraub, R. G. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0166-4 · Cited by 13
Population Diversity and Pharmacogenomics in Africa
Masimirembwa, C. M., Dandara, C., & Hasler, J. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00043-8 · Cited by 15
PET-CMR in heart failure - synergistic or redundant imaging?
Quail, M. A., & Sinusas, A. J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9607-6 · Cited by 13
“The estimated prevalence of coronary artery disease (CAD) in patients with HF ranges from 50 to 65% [16, 17].”
BackgroundHe, W., Kwesiga, M. P., Gebreyesus, E. A., & Liu, S. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.82556 · Cited by 17
“In addition, due to the inspiring clinical outcomes of using isosorbide dinitrate (an NO stimulus) and hydralazine (an antioxidant) to treat patients with symptomatic congestive heart failure [4], we will also discuss how nitroso-redox balance mediates cardiovascular functions.”
BackgroundClinical Characteristics of Hydralazine-induced Lupus
Timlin, H., Michael Shengtao, W. U., Crespo-Bosque, M., Geetha, D., Ingolia, A., Haque, U. J., Towns, M. C., & Grader‐Beck, T. (2019) · Cureus · doi:10.7759/cureus.4996 · Cited by 13
Hui, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_6 · Cited by 13
Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial
Lang, N. N., Dobbin, S. J. H., & Petrie, M. C. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa247 · Cited by 13
Cholesterol, racial variation and targeted medicines
Topol, E. J. (2005) · Nature Medicine · doi:10.1038/nm0205-122 · Cited by 14
Albert, N. M., Moser, D. K., BOEHMER, J. P., Rogers, J. G., Collins, S. P., Starling, R. C., Ezekowitz, J. A., Stevenson, W. G., Givertz, M. M., Tang, W. H. W., et al. (2010) · Cited by 14
Self-citationCallier, S., Cunningham, B. A., Powell, J., McDonald, M. A., & Royal, C. D. M. (2019) · Health Equity · doi:10.1089/heq.2018.0074 · Cited by 13
“As others have explained in detail elsewhere, the African American Heart Failure Trial (A-HeFT), which led to the approval of BiDil, was launched to demonstrate the effectiveness of an isosorbide dinitrate and hydralazine hydrochloride combined pill in self-identified black patients with heart failure, and the investi…”
BackgroundResultChronic kidney disease in patients with cardiac disease: A review of evidence-based treatment
McMurray, J. J. V. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00552.x · Cited by 13
Sankar, P. L. (2006) · New Genetics and Society · doi:10.1080/14636770601032759 · Cited by 15
Pharmacogenetics of multigenic disease: Heart disease as an example
Cooke, G. E. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.011 · Cited by 13
Legal Regulation of the Use of Race in Medical Research
Lillquist, E., & Sullivan, C. A. (2006) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2006.00067.x · Cited by 13
Looking Back and Looking Forward
Shader, R. I. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000153579.07786.c2 · Cited by 13
Greenberg, B., & Mehra, M. R. (2006) · Circulation · doi:10.1161/circulationaha.104.514190 · Cited by 15
Berry, N. C., Sheu, Y.-S., Chesbrough, K., Bishop, R. C., & Vupputuri, S. X. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15193 · Cited by 13
“15,16 These medications make up what is commonly accepted as guideline-directed medical therapy (GDMT) in patients with HFrEF.”
Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
Prenner, S. B., Shah, S. J., & Yancy, C. W. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0603-4 · Cited by 14
Self-citationTereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 13
Anson, M., Zhao, S. S., Essa, H., Austin, P. J., Hernández, G., Lip, G. Y. H., & Alam, U. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.026 · Cited by 15
Novel Strategies and Targets for the Management of Hypertension
TAYLOR, D. A. H. B., & Abdel‐Rahman, A. A. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57008-6 · Cited by 12
Outpatient management of chronic heart failure
Kaldara, E. E., Sanoudou, D., Adamopoulos, S. N., & Nanas, J. N. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978286 · Cited by 13
“The combination of isosorbide dinitrate (ISDN) and hydralazine (HYD) was studied in three large randomized controlled trials, V- HeFT I [127], V-HeFT II (27% black men) [128] and finally the A-HeFT, which included 100% self-identified black patients of both sexes [129].”
MethodMitchell, J. E., Tam, S. W., Trivedi, K., Taylor, A. L., O’Neal, W., Cohn, J. N., & Worcel, M. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.04.022 · Cited by 12
Self-citationSangala, N. C., Lee, R. W., Horsfield, C. J., & Goldsmith, D. J. A. (2009) · International Urology and Nephrology · doi:10.1007/s11255-009-9627-9 · Cited by 12
“However, since the A-HeFT trial in 2004 hydralazine has increasingly been used alongside nitrates in treating African-American patients with NYHA class III and IV heart failure [1].”
MethodFulminating hydralazine‐induced lupus pneumonitis
Birnbaum, B. K., Sidhu, G. S., Smith, R. L., Pillinger, M. H., & Tagoe, C. E. (2006) · Arthritis Care & Research · doi:10.1002/art.21987 · Cited by 12
Heart failure in women is different than in men; should treatment be different?
Mezu, U. L., Bott‐Silverman, C., & Hsich, E. (2007) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.74.6.423 · Cited by 14
Race and the Natural History of Chronic Heart Failure: A Propensity-Matched Study
Gambassi, G., Agha, S. A., Sui, X., Yancy, C. W., Butler, J., Giamouzis, G., Love, T. E., & Ahmed, A. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.02.004 · Cited by 12
Self-citationShah, K. B., Kop, W. J., Christenson, R. H., Diercks, D. B., Kuo, D. C., Henderson, S., Hanson, K., & deFilippi, C. R. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.09.007 · Cited by 12
Bonsu, K. O., Owusu, I. K., Buabeng, K. O., Reidpath, D. D., & Kadirvelu, A. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004706 · Cited by 14
ANA-Negative Hydralazine-Induced Pericardial Effusion
Zeitjian, V., & Mehdizadeh, A. (2017) · Case Reports in Medicine · doi:10.1155/2017/3521541 · Cited by 12
“published in the NEJM in 2004, there has been an increase in the amount of hydralazine prescribed in patients with heart failure [2, 11].”
BackgroundContemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Egbuche, O., Hanna, B., Onuorah, I., Uko, E., Taha, Y., Ghali, J. K., & Onwuanyi, A. (2019) · Current Cardiology Reviews · doi:10.2174/1573403x15666190709185011 · Cited by 13
Advances in the Management of Acute Decompensated Heart Failure
Mitter, S. S., & Pinney, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.002 · Cited by 16
Sudden Cardiac Death and Heart Failure
Thompson, B. S. (2009) · AACN Advanced Critical Care · doi:10.1097/nci.0b013e3181b82379 · Cited by 12
Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure
Chirkov, Y. Y., Sciscio, M. D., Sverdlov, A. L., Leslie, S., Sage, P. R., & Horowitz, J. D. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6233-0 · Cited by 12
“While the design of A-HeFT was based on post-hoc population sub-analyses of V-HeFT1 and V-HeFT-2 [1, 4], indicating potential for greater responsiveness to hydralazine/ISDN in African–Americans, a previous study by Elkayam and co-workers [24] documented potentiation of nitrate effect by hydralazine in a patient group…”
BackgroundMethodResultInfluentialAslam, S. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f313bd · Cited by 13
Rice, K. L., Leimer, I., Kesten, S., & Niewoehner, D. E. (2008) · Translational research · doi:10.1016/j.trsl.2008.05.011 · Cited by 12
Zhao, S. X., Lee, L. M., Nearing, B. D., Busso, V. O., Kwaku, K. F., & Verrier, R. L. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000244677.49969.73 · Cited by 12
“Clinical trials reveal a statistically significant reduction in mortality among postmyocardial infarction and selected heart failure patients treated with oral nitrates.(6,7) Mechanisms for the potent antiarrhythmic effects of”
BackgroundCardiology: Treatment of Systolic Heart Failure in the Elderly: An Evidence-Based Review
Arif, S. A., Mergenhagen, K. A., Carpio, R. O. D. D., & Ho, C. I. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p128 · Cited by 13
Girerd, N., Zannad, F. M., & Rossignol, P. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.06.004 · Cited by 14
Benefit–risk review of different drug classes used in chronic heart failure
Andries, G., Yandrapalli, S., & Aronow, W. S. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1512580 · Cited by 13
Facts and Fictions: BiDil and the Resurgence of Racial Medicine
Dorr, G. M., & Jones, D. S. (2008) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2008.289.x · Cited by 12
Pay-for-performance--financial health disparities and the impact on healthcare disparities.
Hood, R. G. (2007) · PubMed Central · Cited by 12
Vines, A. I., & Godley, P. A. (2004) · North Carolina Medical Journal · doi:10.18043/ncm.65.6.341 · Cited by 15
Cardiovascular Effects of Cancer Therapy
Briston, D. A., Cochran, T. R., Sambatakos, P., Brown, S. R., & Lipshultz, S. E. (2015) · Pediatric oncology · doi:10.1007/978-3-319-16435-9_10 · Cited by 12
Pharmacologic Options for Treatment of Ischemic Disease
Abrams, J., Schroeder, J. S., Frishman, W. H., & Freedman, J. E. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50011-5 · Cited by 14
Shahzad, M., Ahmed, S., Ahsan, M., Zulfiqar, E., Hurjkaliani, S., Thakur, T., Khan, R., Sethi, P., Daoud, M., & Goyal, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-04056-7 · Cited by 11
“Emerging therapies, such as non-steroidal MRAs and novel vasodilatory agents, may provide additional options for patients with coexisting HF and CKD, underscoring the need for further research to refine treatment strategies 99,105 .”
Machines Versus Medication for Biventricular Heart Failure: Focus On the Total Artificial Heart
Arabía, F. A., & Moriguchi, J. D. (2014) · Future Cardiology · doi:10.2217/fca.14.47 · Cited by 11
Tamargo, J. L., Rosano, G. M. C., Delpón, E., Ruilope, L. M., & Lopez-Sendon, J. L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.124 · Cited by 11
The Medical Treatment of Stable Angina
Kwon, L., & Rosendorff, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00020-0 · Cited by 12
Lee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
Kourek, C., Briasoulis, Α., Papamichail, A., Xanthopoulos, A. V., Tsougos, E., Farmakis, D. T., & PARASKEVAIDIS, I. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063113 · Cited by 14
“Additionally, the African American Heart Failure Trial showed a 43% reduction in the risk of death or hospitalization for HF in black patients with NYHA class III or IV HF who received a combination of isosorbide dinitrate and hydralazine compared to those who received placebo [36].”
BackgroundAn Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S. A., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 13
“The The African American Heart Failure Trial (A-HeFT) trial sought to explore this difference by recruiting patients who self-identify as black (defined as of African descent) with LVEF 35% or a dilated left ventricle with a LVEF of 45% [183].”
BackgroundWhen Should We Use Nitrates in Congestive Heart Failure?
Vizzardi, E., Bonadei, I., Rovetta, R., D’Aloia, A., Quinzani, F., Curnis, A., & Cas, L. D. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2012.00311.x · Cited by 11
“A-Heft [31] Black patients who had New York Heart Association class III or IV heart failure with average EF 30% (n = 1050) H-ISDN 225–120 mg/daily (n = 518) versus placebo (n= 532) Total mortality First hospitalization for heart failure 10.”
Heart failure therapy: beyond the guidelines
Thompson, K. A., Bharadwaj, P., Philip, K. J., & Schwarz, E. R. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32833d3566 · Cited by 11
Group-Based and Personalized Care in an Age of Genomic and Evidence-Based Medicine: A Reappraisal
Maglo, K. N. (2012) · Perspectives in biology and medicine · doi:10.1353/pbm.2012.0006 · Cited by 14
A Rationale for Epigenetic Repurposing of Hydralazine in Chronic Heart and Kidney Failure
Zeisberg, E. M., & Zeisberg, M. (2016) · Journal of Clinical Epigenetics · Cited by 11
Heart Failure Guidelines on Pharmacotherapy
Papadimitriou, L., HAMO, C. E., & Butler, J. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_24 · Cited by 12
Pharmacologic Management for Heart Failure and Emerging Therapies
Kim, D. H., Chien, F.-J., & Eisen, H. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0899-x · Cited by 11
What's Next for Acute Heart Failure Research?
Collins, S. P., Levy, P. D., Fermann, G. J., Givertz, M. M., Martindale, J., Pang, P. S., Storrow, A. B., Diercks, D., Felker, G. M., Fonarow, G. C., et al. (2017) · Academic Emergency Medicine · doi:10.1111/acem.13331 · Cited by 11
“Conversely, in the setting of AHF there are far weaker II-B recommendations for the use of nitroglycerin (NTG) or other IV vasodilators, and the precise patients in whom this therapy needs to be utilized is poorly characterized.(21-25) The lack of robust data, combined with the additional monitoring and titration nece…”
BackgroundMethodContemporary approach to treating heart failure
Brann, A. M., Tran, H. A., & Greenberg, B. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.011 · Cited by 15
Hydralazine–Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis
Mavrakanas, T. A., Soomro, Q. H., & Charytan, D. M. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.03.032 · Cited by 11
Abraham, W. T., Massie, B. M., Lukas, M. A., Lottes, S. R., Nelson, J. J., Fowler, M. B., Greenberg, B., Gilbert, E. M., & Franciosa, J. A. (2007) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2007.888111.x · Cited by 11
Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era
Reiffel, J. A. (2005) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484050100i406 · Cited by 13
“A-HeFT = African-American Heart Failure Trial (20) AIRE = Acute Infarction Ramipril Efficacy (41) ATLAS = Assessment of Treatment With Lisinopril and Survival (16) AMIOVIRT = Amiodarone versus Implantable Cardioverter-Defibrillator Trial (69) AVID = Antiarrhythmics versus Implantable Defibrillators (63) BEST = Beta-Bl…”
BackgroundMethodAngiotensin receptor–neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs
Gori, M., Volterrani, M., Piepoli, M. F., & Senni, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.083 · Cited by 14
Update of treatment of heart failure with reduction of left ventricular ejection fraction
Aronow, W. S. (2016) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2016.63002 · Cited by 12
“At 10-month follow-up, isosorbide dinitrate plus hydralazine reduced mortality by 43% and rate of first hospitalization for HFrEF by 33% [28].”
BackgroundMethodTeerlink, J. R., Sliwa, K. S., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00015-6 · Cited by 17
Patenting Race in a Genomic Age1
Kahn, J. (2008) · Genomics Society and Policy · doi:10.1186/1746-5354-4-3-46 · Cited by 11
BNP for Clinical Monitoring of Heart Failure
Troughton, R. W., & Richards, M. (2006) · Heart Failure Clinics · doi:10.1016/j.hfc.2006.08.006 · Cited by 11
Nicorandil – Review of Pharmacological Properties and Clinical Applications
Schmid, J., & Schroeder, V. (2005) · Heart Drug · doi:10.1159/000089603 · Cited by 12
“have been confirmed in black patients, a subgroup that had a particularly favorable response to isosorbide dinitrate plus hydralazine in retrospective analyses [”
BackgroundManagement Strategies for Stage‐D Patients with Acute Heart Failure
Feldman, D., Menachemi, D. M., Abraham, W. T., & Wexler, R. (2007) · Clinical Cardiology · doi:10.1002/clc.20251 · Cited by 11
Swindle, J. P., Burroughs, T. E., Schnitzler, M. A., & Hauptman, P. J. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.04.003 · Cited by 11
Hypertension: A Review and Rationale of Treatment
Copley, J. B., & Rosario, R. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.10.004 · Cited by 11
McDonald, K. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.01.013 · Cited by 15
“While the few data available indicate potential for further symptomatic improvement, and possibly improvement in prognosis in African-Americans with the addition of hydralazine and nitrates, the information to hand at present does not allow for the development of precise guidelines [31].”
BackgroundEadon, M. T., Hein, D. W., Andersen, M. A., Chapman, A. B., Cooper‐DeHoff, R. M., Desta, Z., Duarte, J. D., Elchynski, A. L., Gaedigk, A., Karol, S. E., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70071 · Cited by 11
Exploring Heart Failure Mortality Trends and Disparities in Women: A Retrospective Cohort Analysis.
Ibrahim, R., Shahid, M., Tan, M., Martyn, T., Lee, J., & William, P. (2023) · American Journal of Cardiology · doi:10.1016/j.amjcard.2023.09.087 · Cited by 8
Medical Management and Device-Based Therapies in Chronic Heart Failure
Nguyen, A. H., Hurwitz, M., Abraham, J. A., Blumer, V. L., Flanagan, M. C., Garan, A. R., Kanwar, M. K., Kataria, R., Kennedy, J. L. W., Kochar, A., et al. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101206 · Cited by 14
“23 The V-HeFT I trial was a multicenter, double-blinded, parallel-group RCT that randomized 642 patients at 11 Veterans Affairs centers in the United States with symptomatic chronic compensated systolic HFrEF from 1980 to 1985 to combination H-ISDN, prazosin, or placebo.”
BackgroundStrategies for improving diversity, equity, and inclusion in cardiovascular research: a primer
Prichard, R. A., Maneze, D., Straiton, N., Inglis, S. C., & McDonagh, J. (2024) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvae002 · Cited by 10
Onyebeke, C. O., Zhang, D. T., Musse, M., Ünlü, O., Nahid, M., Ambrosy, A. P., Levitan, E. B., Safford, M. M., & Goyal, P. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101126 · Cited by 10
Management of Chronic Cardiorenal Syndrome
Attanasio, P., Ronco, C., Anker, M. S., Ponikowski, P. P., & Anker, S. D. (2010) · Contributions to nephrology · doi:10.1159/000313751 · Cited by 10
Mango, R., Vecchione, L., Raso, B., Borgiani, P., Brunetti, E., Mehta, J. L., Lauro, R., Romeo, F., & Novelli, G. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.15.2565 · Cited by 13
Schmid, W., Lee, A., Son, J., Koller, E., & Volf, I. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.05.002 · Cited by 13
Sharma, K. H., & Jindal, A. (2014) · Archives of Medicine and Health Sciences · doi:10.4103/2321-4848.144359 · Cited by 10
Çavuşoğlu, Y., Altay, H., Ekmekçi, A., Eren, M., Küçükoğlu, M. S., Nalbantgil, S., Sarı, İ., Selçuk, T., Temizhan, A., Ural, D., et al. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6767 · Cited by 12
“The A-HeFT Trial (25), including African-American subjects, was terminated early due to a 43% (p<0.”
BackgroundMethodInfluentialRichardson, A., Tolley, E. A., Hartmann, J., Reedus, J., Bowlin, B., Finch, C. K., Sands, C. W., & Self, T. H. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.09.008 · Cited by 10
Albert, N. M., Antol, D. D., DeClue, R. W., Casebeer, A. W., Li, Y., Stemkowski, S., & Chang, C.-L. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0618-4 · Cited by 10
Responder to BNP-guided treatment in heart failure. The process of defining a responder
Karlström, P., Dahlström, U., Boman, K., & Alehagen, U. (2015) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2015.1070961 · Cited by 10
High‐Impact Articles Related to the Management of Heart Failure: 2008 Update
Jackevicius, C. A., Page, R. L., II, Chow, S. L., Dunn, S. P., Lee, C. R., Ng, T. M. H., Rodgers, J. E., Vardeny, O., Wiggins, B. S., & Munger, M. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.1.82 · Cited by 11
The attitudes and views of GPs and physicians to prescribing by heart failure nurse specialists
Shannon, E., & Spence, W. D. (2011) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2011.6.9.450 · Cited by 10
Being Specific About Race-Specific Medicine
Kahn, J., & Sankar, P. L. (2006) · Health Affairs · doi:10.1377/hlthaff.25.w375 · Cited by 10
Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting
Riba, A. L. (2008) · Critical Care Clinics · doi:10.1016/j.ccc.2007.09.002 · Cited by 13
Managing Acute Decompensated Heart Failure
Pauly, D. F. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.011 · Cited by 11
Blankstein, R., & Bakris, G. L. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.03.007 · Cited by 10
Ofili, E., Igho-Pemu, P. E., Lapu-Bula, R., Quarshie, A., Obialo, C. I., Thomas, C., Onwuanyi, A., Onwanyi, A., Odwole, A., Oduwole, A., et al. (2005) · PubMed · Cited by 10
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.